Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, announces the appointment of Khalil Barrage as Interim Chair of the Board.
- Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, announces the appointment of Khalil Barrage as Interim Chair of the Board.
- Sensorion has commenced a search process to appoint a new independent Chair of the Board and will provide an update in due course.
- “Khalil Barrage is a seasoned investment professional with decades of experience investing in and supporting private and public life sciences companies.
- This is the right team to move Sensorion and its innovative product candidates forward and I’m excited to be working with them.”